Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Britain Courts Anthropic Amid US Defense Department Dispute 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
ATLANTA, Sept. 07, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the following upcoming conferences:
- Rodman & Renshaw 18th Annual Global Investment Conference at 4:15 p.m. ET on Tuesday, September 13, 2016 in New York, NY. Link: http://wsw.com/webcast/rrshq26/avir
- Ladenburg Thalmann 2016 Healthcare Conference at 2:30 p.m. ET on Tuesday, September 27, 2016 in New York, NY. Link: http://wsw.com/webcast/ladenburg2/avir
A live audio webcast of each presentation can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.aviragentherapeutics.com. An archived replay of the webcast will be available for 30 days after the live event concludes.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
